209 related articles for article (PubMed ID: 16368038)
1. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO).
Emkey R; Koltun W; Beusterien K; Seidman L; Kivitz A; Devas V; Masanauskaite D
Curr Med Res Opin; 2005 Dec; 21(12):1895-903. PubMed ID: 16368038
[TBL] [Abstract][Full Text] [Related]
2. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II).
Hadji P; Minne H; Pfeifer M; Bourgeois P; Fardellone P; Licata A; Devas V; Masanauskaite D; Barrett-Connor E
Joint Bone Spine; 2008 May; 75(3):303-10. PubMed ID: 18069036
[TBL] [Abstract][Full Text] [Related]
3. Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO).
Iwamoto J; Okano H; Furuya T; Urano T; Hasegawa M; Hirabayashi H; Kumakubo T; Makita K
J Bone Miner Metab; 2016 Mar; 34(2):201-8. PubMed ID: 25794468
[TBL] [Abstract][Full Text] [Related]
4. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
Pyon EY
Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
[TBL] [Abstract][Full Text] [Related]
6. Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.
Chung YS; Lim SK; Chung HY; Lee IK; Park IH; Kim GS; Min YK; Kang MI; Chung DJ; Kim YK; Choi WH; Shong MH; Park JH; Byun DW; Yoon HK; Shin CS; Lee YS; Kwon NH
Calcif Tissue Int; 2009 Nov; 85(5):389-97. PubMed ID: 19816648
[TBL] [Abstract][Full Text] [Related]
7. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate.
Kendler D; Kung AW; Fuleihan Gel-H; González González JG; Gaines KA; Verbruggen N; Melton ME
Maturitas; 2004 Jul; 48(3):243-51. PubMed ID: 15207890
[TBL] [Abstract][Full Text] [Related]
8. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
Miller PD; Epstein S; Sedarati F; Reginster JY
Curr Med Res Opin; 2008 Jan; 24(1):207-13. PubMed ID: 18042311
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials.
Lee YH; Song GG
Korean J Intern Med; 2011 Sep; 26(3):340-7. PubMed ID: 22016595
[TBL] [Abstract][Full Text] [Related]
10. Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.
Binkley N; Martens MG; Silverman SL; Derman RJ; Greenwald M; Kohles JD; Bachmann GA
South Med J; 2009 May; 102(5):486-92. PubMed ID: 19373149
[TBL] [Abstract][Full Text] [Related]
11. Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate.
Bonnick SL; Silverman S; Tanner SB; Martens M; Bachmann G; Kohles JD; Civitelli R
J Womens Health (Larchmt); 2009 Jul; 18(7):935-43. PubMed ID: 19563245
[TBL] [Abstract][Full Text] [Related]
12. Once-monthly dosing: an effective step forward.
Reid DM
Bone; 2006 Apr; 38(4 Suppl 1):S18-22. PubMed ID: 16533625
[TBL] [Abstract][Full Text] [Related]
13. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study.
Simon JA; Lewiecki EM; Smith ME; Petruschke RA; Wang L; Palmisano JJ
Clin Ther; 2002 Nov; 24(11):1871-86. PubMed ID: 12501880
[TBL] [Abstract][Full Text] [Related]
14. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.
Gold DT; Safi W; Trinh H
Curr Med Res Opin; 2006 Dec; 22(12):2383-91. PubMed ID: 17257452
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis.
Guañabens N; Monegal A; Cerdá D; Muxí Á; Gifre L; Peris P; Parés A
Hepatology; 2013 Dec; 58(6):2070-8. PubMed ID: 23686738
[TBL] [Abstract][Full Text] [Related]
16. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study.
Cooper A; Drake J; Brankin E;
Int J Clin Pract; 2006 Aug; 60(8):896-905. PubMed ID: 16800837
[TBL] [Abstract][Full Text] [Related]
17. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
[TBL] [Abstract][Full Text] [Related]
18. Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study.
Kastelan D; Lozo P; Stamenkovic D; Miskic B; Vlak T; Kolak Z; Milas Ahic J; Altabas V; Crncevic Orlic Z; Korsic M
Clin Rheumatol; 2009 Mar; 28(3):321-6. PubMed ID: 19031095
[TBL] [Abstract][Full Text] [Related]
19. Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.
Blumentals WA; Harris ST; Cole RE; Huang L; Silverman SL
Ann Pharmacother; 2009 Apr; 43(4):577-85. PubMed ID: 19318598
[TBL] [Abstract][Full Text] [Related]
20. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
Miller PD; McClung MR; Macovei L; Stakkestad JA; Luckey M; Bonvoisin B; Reginster JY; Recker RR; Hughes C; Lewiecki EM; Felsenberg D; Delmas PD; Kendler DL; Bolognese MA; Mairon N; Cooper C
J Bone Miner Res; 2005 Aug; 20(8):1315-22. PubMed ID: 16007327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
